CHINA NATIONAL MEDICINES CORP (600511) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥13.56 billion, up 6.63% year-over-year.

• Net profit attributable to shareholders was ¥474.26 million, a 3.32% increase year-over-year.

• Basic and diluted EPS both rose to ¥0.6286, up 3.32% from the prior year.

Financial highlights

• Operating income for Q1 2026 was ¥606.78 million, up 0.15% year-over-year.

• Total assets at quarter-end were ¥36.18 billion, down 1.39% from year-end 2025.

• Net cash flow from operating activities was negative ¥3.59 billion, a further decline from the previous year.

• Shareholders’ equity increased 2.70% to ¥19.05 billion compared to year-end 2025.

Outlook and guidance

• No explicit forward-looking guidance provided, but the report emphasizes continued operational stability and compliance.